May 29, 2020 09:42 AM EDT

As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug

Natalie Grover

Reporter

In a world now brimming with checkpoint inhibitors, companies often struggle to make a mark given a raft of therapies have already captured a considerable …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug

Natalie Grover

Reporter

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus